Abstract

Antibodies of the IgG class to terminal Galα3Gal (IgG anti-αGal) is abundant in human plasma and are reported to bind most sepsis-causing Gram-negative bacteria. However, these seminal findings, made more than two decades ago, have not been reexamined. Our aim was to assess IgG anti-αGal´s pathogen reactivity. We affinity purified IgG anti-αGal from a therapeutic grade normal human IgG pool applying two rounds of positive selection with Galα3Gal-coupled beads and included removal of column matrix reactive antibodies. The purified antibodies were rigorously characterized in terms of specificity and purity in various solid-phase immunoassays. We used flow cytometry to study reactivity against 100 consecutive clinical isolates diagnosed as cause of sepsis in humans. We found that the purified IgG anti-αGal displays high specificity for Galα3Gal. Also, IgG anti-αGal at 5 mg/L bound 56 out of 100 pathogens with predilection for Gram-positive bacteria binding 39 out of 52 strains. We confirm that although IgG anti-αGal comprise a small fraction of the human antibody pool (~0.1%), these antibodies targets an impressively large part of pathogens causing invasive disease.

Highlights

  • Antibodies of the IgG class to terminal Galα3Gal (IgG anti-αGal) is abundant in human plasma and are reported to bind most sepsis-causing Gram-negative bacteria

  • One group of human antibodies, IgG antibodies against the carbohydrate structure terminal Galα3Gal (IgG anti-αGal), were more than twenty years ago reported to bind most of sepsis-causing Gram-negative bacterial pathogens, including Escherichia coli and species of Klebsiella, Enterobacter, Serratia, Citrobacter, Proteus, and Pseudomonas[2,3]

  • We found that Glcα2Fru had essentially no effect, Galα6Glc inhibited at most half of reactivity, and Galα3Gal inhibited most reactivity (Fig. 5C), thereby confirming specificity of the binding to E. coli O86

Read more

Summary

Introduction

Antibodies of the IgG class to terminal Galα3Gal (IgG anti-αGal) is abundant in human plasma and are reported to bind most sepsis-causing Gram-negative bacteria. One group of human antibodies, IgG antibodies against the carbohydrate structure terminal Galα3Gal (IgG anti-αGal), were more than twenty years ago reported to bind most of sepsis-causing Gram-negative bacterial pathogens, including Escherichia coli and species of Klebsiella, Enterobacter, Serratia, Citrobacter, Proteus, and Pseudomonas[2,3]. This broad pathogen reactivity is of interest in the context of developing new therapeutic measures.

Objectives
Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call